[ad_1]
- Brings over 20 years of medical expertise, together with administration of Section 1-2 medical trials in quite a lot of indications similar to ophthalmology
- Will oversee all R&D operations with concentrate on medical improvement and operations
Kensington, MD, USA – EQS Newswire – 25 October 2023 – Galimedix Therapeutics, Inc. (“Galimedix”), a Section 2 clinical-stage biotechnology firm growing novel oral and topical neuroprotective therapies with the potential to revolutionize the remedy of great eye and mind ailments, at this time introduced the appointment of Luciana Summo, PhD, as Vice President, R&D Operations. On this newly created place, she is going to oversee all actions associated to R&D operations, with an emphasis on medical improvement and operations. This consists of spearheading the design, planning, and execution of medical trials. Dr. Summo experiences to Hermann Russ, MD, PhD, Co-founder and Chief Scientific Officer.
“We’re delighted to welcome Luciana to Galimedix,” stated Alexander Gebauer, MD, PhD, Co-founder and Government Chairman. “She brings robust expertise establishing and operating medical trials and making certain that the entire correct assist constructions are put in place. As we transfer our lead product candidate, GAL-101, into Section 2 testing for the remedy of dry age-related macular degeneration, her talent set is the right match for this subsequent stage in our improvement. Luciana will play a pivotal position in defining Galimedix’s general R&D technique and driving our R&D initiatives ahead. All of us very a lot stay up for working together with her as we contribute to advancing revolutionary healthcare options which have the potential to enhance the lives of sufferers.”
Dr. Summo has over 20 years of expertise in medical improvement and operations, together with the administration of Section 1-2 medical trials in a number of indications similar to ophthalmology, cardiology, and oncology. Previous to becoming a member of Galimedix, she labored in positions of accelerating accountability within the medical departments at OMEICOS Therapeutics GmbH, NOXXON Pharma AG, and Berlin-Chemie AG/ Menarini Group. She is properly versed in establishing and overseeing medical trials on a world scale and has performed a key position in transitioning applications from pre-clinical to medical stage. She has expertise with all the spectrum of actions associated to R&D operations, with a particular emphasis on medical improvement and medical operations, together with additionally high quality administration and CMC. She works carefully with cross-functional groups, together with CROs, scientists, clinicians, regulatory affairs specialists, and totally different stakeholders, to make sure that trials are carried out in accordance with rigorous scientific requirements and regulatory pointers. Dr. Summo has expertise in submitting Medical Trial Purposes (CTAs) in Europe and Investigational New Drug (IND) purposes within the US and ready for and took part in pre-IND conferences with the US Meals and Drug Administration (FDA), in addition to regulatory company conferences in Europe. She additionally has arrange from scratch and run a medical operations division.
Luciana Summo, PhD, Vice President, R&D Operations, added: “I’m actually excited to be becoming a member of Galimedix at this vital level within the Firm’s development. The applications in ophthalmology and Alzheimer’s illness have the potential to vary the remedy paradigm, and I stay up for working with the remainder of the group to carry them ahead within the clinic.”
Hashtag: #Galimedix
The issuer is solely answerable for the content material of this announcement.
About Galimedix Therapeutics, Inc.
Galimedix is a Section 2 clinical-stage non-public firm growing novel oral and topical neuroprotective therapies with the potential to revolutionize the remedy of great eye and mind ailments. Based by a seasoned and extremely devoted group of bio-entrepreneurs, pharmaceutical executives and scientists, Galimedix’s groundbreaking small molecules supply the hope of fixing the course of illness the place amyloid beta (Aβ) performs a task, similar to in dry age-related macular degeneration (AMD), glaucoma and Alzheimer’s illness – Galimedix’s preliminary areas of focus. The Firm’s strategy targets poisonous Aβ oligomers and protofibrils. Many research have indicated that these oligomers and protofibrils are an underlying reason for neurodegenerative ailments of the attention. And, latest approvals and promising Section 3 outcomes of anti-Aβ medicine even have validated them as a key goal in Alzheimer’s illness. Compelling pre-clinical knowledge assist the potential of Galimedix’s product candidates to gradual or cease neurodegeneration and in addition restore misplaced neuronal operate. A Section 2 proof-of-concept examine in dry AMD with lead program, topical GAL-101, is in preparation with robust assist from accomplice, Théa Open Innovation (TOI). Medical research in different indications are deliberate.
[ad_2]
Source link
